BioSpace News Archive

- Lead clinical program, an EGFR / TGFβ-trap bifunctional antibody, rapidly enrolling a Phase 1/2 study in leading research hospitals in U.S. and Canada - $40 million in seed financing from global pharmaceutical company Biocon, Ltd. - International R&D team brings strong track record of developing FDA-approved therapies

Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company’s Lead Product Candidate Vicineum™ Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 2021 1

Seisa Medical Inc., a full-service provider of integrated manufacturing and development services to the medical device industry, today announced that it has acquired Bay Area-based businesses ProtoQuick, Inc. and Peridot Corporation.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and provided an update on clinical trial activities.

Results of a clinical study conducted by researchers in Manaus, Brazil, show that the Gazelle® Malaria test outperformed Rapid Diagnostic Tests (RDTs) and was nearly as accurate as more expensive and time-consuming expert microscopy in detecting Plasmodium vivax (P. vivax) malaria.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that PEPAXTO® (melphalan flufenamide) is now commercially available and that the first patients are being treated with the drug.

Continued Strong Growth and Increasing Momentum for Invisalign Clear Aligners and iTero Systems and Services Across Products and Customer Channels Worldwide, Reflects the Strength of Align’s Doctor-Directed Model and the Align Digital Platform

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP), in collaboration with Pfizer Inc., announces ten projects have been chosen to receive funding to support innovative approaches to improve the processes related to appropriate biosimilar adoption in oncology.

CuraSen Therapeutics, Inc., a privately held, clinical-stage biotechnology company, announced Phase 1 proof-of-principle data demonstrating that salbutamol, a drug approved to treat respiratory disease, significantly improved brain perfusion as measured by increased cerebral blood flow (CBF) in healthy subjects.

Veracyte, Inc. (Nasdaq: VCYT) today announced it has completed its acquisition of Decipher Biosciences, Inc. to further solidify its global leadership in genomic diagnostics, with an expanded reach into 7 of the 10 most common cancers in the United States, while accelerating revenue growth.